330 related articles for article (PubMed ID: 12569609)
21. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas.
Li H; Wang Q; Gao F; Zhu F; Wang X; Zhou C; Liu C; Chen Y; Ma C; Sun W; Zhang L
Oncol Rep; 2008 Sep; 20(3):573-9. PubMed ID: 18695908
[TBL] [Abstract][Full Text] [Related]
22. Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma.
Preuss SF; Weinell A; Molitor M; Semrau R; Stenner M; Drebber U; Wedemeyer I; Hoffmann TK; Guntinas-Lichius O; Klussmann JP
Head Neck; 2008 Oct; 30(10):1318-24. PubMed ID: 18704972
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.
Kawasaki H; Altieri DC; Lu CD; Toyoda M; Tenjo T; Tanigawa N
Cancer Res; 1998 Nov; 58(22):5071-4. PubMed ID: 9823313
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
27. Survivin expression in atypical adenomatous hyperplasia of the lung.
Nakanishi K; Kawai T; Kumaki F; Hiroi S; Mukai M; Ikeda E
Am J Clin Pathol; 2003 Nov; 120(5):712-9. PubMed ID: 14608897
[TBL] [Abstract][Full Text] [Related]
28. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
[TBL] [Abstract][Full Text] [Related]
29. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining.
Hwang SL; Hong YR; Chai CY; Lin HJ; Howng SL
Kaohsiung J Med Sci; 1998 Oct; 14(10):607-15. PubMed ID: 9819502
[TBL] [Abstract][Full Text] [Related]
30. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
31. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers.
Sharma H; Sen S; Mathur M; Bahadur S; Singh N
Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041
[TBL] [Abstract][Full Text] [Related]
32. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
33. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
34. Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis.
Kristt DA; Yarden Y
Cancer; 1996 Sep; 78(6):1272-83. PubMed ID: 8826951
[TBL] [Abstract][Full Text] [Related]
35. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
[TBL] [Abstract][Full Text] [Related]
36. Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.
Tsunoda K; Kitange G; Anda T; Shabani HK; Kaminogo M; Shibata S; Nagata I
Brain Tumor Pathol; 2005; 22(2):79-87. PubMed ID: 18095109
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
38. hTERT immunopositivity patterns in the normal brain and in astrocytic tumors.
Kotoula V; Cheva A; Barbanis S; Papadimitriou CS; Karkavelas G
Acta Neuropathol; 2006 Jun; 111(6):569-78. PubMed ID: 16614861
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.
Liu X; Chen N; Wang X; He Y; Chen X; Huang Y; Yin W; Zhou Q
J Neuropathol Exp Neurol; 2006 Sep; 65(9):905-13. PubMed ID: 16957584
[TBL] [Abstract][Full Text] [Related]
40. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.
Tanaka K; Iwamoto S; Gon G; Nohara T; Iwamoto M; Tanigawa N
Clin Cancer Res; 2000 Jan; 6(1):127-34. PubMed ID: 10656440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
